IVD Multi-Model Grouping for Overseas Registration: A Strategic Approach

For overseas registration of IVD products, grouping multiple models into a single submission is a key strategy to reduce registration costs and shorten time to market. Manufacturers must first determine whether the target country regulates IVDs as medical devices, then classify the product by risk (e.g., EU IVDR Classes A, B, C, D; China Classes I, II, III; FDA Class I, II, III) to select the appropriate registration path. Grouping is generally based on identical intended use, similar technical principles, consistent main materials, and comparable performance indicators. Under the EU IVDR, for example, a single “device group” can be submitted as a combined technical file, but a description of differences and validation data for each model must be provided.

Scope and Core Issues

Manufacturers searching for “IVD multi-model grouping for overseas registration” are typically not looking for a conceptual explanation but for practical judgment: whether existing documentation can support submissions in target markets, whether a local agent or authorized representative is required, why timelines are extended, and which issues can affect launch plans. This question often involves product classification, registration pathway, evidence chain, label localization, and post-market responsibilities.

If a company plans to enter multiple GHWP member states or markets in Southeast Asia, the Middle East, and Latin America, answering one country’s process alone is insufficient. A more effective approach is to first make the core technical file, quality management system certificate, performance validation, clinical evidence, and labels/instructions reusable, then localize them according to each country’s regulatory requirements.

Regulatory Determination Logic

Step 1: Determine whether the product falls within the scope of medical device regulation in the target country. For example, in GHWP member states (China, ASEAN, Japan, Korea, etc.), IVDs are generally regulated as medical devices, but some countries may have separate classifications.

Step 2: Determine the risk class. The EU IVDR has Classes A, B, C, D; China uses Classes I/II/III; the US FDA uses Class I/II/III. The risk class directly determines the registration route (notified body review, self-declaration, PMA, etc.).

Step 3: Evaluate reusability of existing documentation. If NMPA, CE, FDA, ISO 13485, or MDSAP certifications are already in place, analyze which technical documents (e.g., risk management, performance evaluation, clinical evaluation) can be adopted directly and which need localization.

Step 4: Confirm the feasibility of grouping. Common grouping criteria include: identical intended use, same analyte, same use environment (professional/self-testing), same detection principle (e.g., chemiluminescence, immunochromatography), and equivalent key performance indicators (sensitivity, specificity, precision). For models with the same principle but different platforms or specifications, bridging data should be provided.

Documentation and Evidence

Typical documentation includes product description, model/specification matrix, intended use, classification rationale, ISO 13485 or applicable QMS certificate, technical file, performance verification report, risk management file, clinical evaluation or clinical evidence, labels and instructions, authorization documents, existing registration certificates, manufacturer declarations, and post-market surveillance (PMS) documentation.

The quality of documentation depends on consistency, not quantity. Claims in the instructions, test report model coverage, scope of clinical evidence, risk management conclusions, label warnings, and registration application information must support each other. Regulators are concerned about whether the product is safe, effective, and traceable for its intended use—not how many files the manufacturer uploads.

Common Mistakes

• Submitting a direct translation of domestic NMPA files without restructuring the evidence for the target market pathway.
• Including too many models/specifications without sufficient coverage in test reports, clinical evidence, or labeling.
• Choosing a local agent based solely on sales capability without defining regulatory responsibility, certificate control, and post-market obligations.
• Inconsistencies among labels, instructions, promotional materials, and registration submissions, leading to deficiency letters or post-market compliance risk.
• Failing to plan multi-country document reuse, resulting in repetitive work and increased cost and timeline for each country.

Manufacturer Preparation Checklist

• Confirm the regulatory classification and registration path in the target country (via local agent or consultant).
• Build a model differentiation matrix listing all parameters, materials, software versions, etc.
• Prepare performance verification data: at least precision, accuracy, linearity, reference interval; comparative data for grouped models.
• Ensure the risk management report covers all models and analyzes whether differences introduce new risks.
• If applicable, the clinical evaluation report should cover representative models and justify extrapolation.
• Localized documents: labels, instructions, packaging drafts in the required language.
• QMS documents: ISO 13485 certificate or equivalent.
• Local agent/authorized representative contact details and signed agreement.
• Post-market surveillance (PMS) plan and periodic safety update report (PSUR) templates.
• Registration application form and other documents required by the authority (e.g., free sale certificate, certificate of manufacture).

AIMEILI Regulatory Interpretation and Business Impact

AIMEILI Perspective

The most common misjudgment is assuming that similar product names are sufficient for grouping, while overlooking technical differences. We recommend conducting a “grouping feasibility assessment” at the project stage, listing all models and checking them against the target country’s grouping requirements. Performance data in the technical file is the core of reuse—especially for products already approved by CE or FDA, their performance reports, risk management documents, and clinical evaluation reports can save significant time. However, local conversion is essential: for example, China requires Chinese instructions and performance testing per YY/T standards, while ASEAN countries may accept English but require a local representative.

Certificate control is also critical: if a foreign local agent holds the registration certificate, the manufacturer may be passive during changes or renewals. We recommend that companies hold the certificate themselves or sign a strict agreement with a reliable agent. For multi-country registration, establish a “core document library” and a “country gap list” to avoid repetitive work and reduce deficiency risk.

Frequently Asked Questions

Q: Can different package sizes (e.g., 50 tests and 100 tests) be grouped?
Yes, provided that all components and fill volumes per unit are identical except for package size, and performance is equivalent. The technical file should explain the package size difference and demonstrate no impact on stability. Some countries (e.g., Brazil) may require separate registration for each package size; consult in advance.

Q: Can the same analyte with different detection principles (e.g., ELISA vs. chemiluminescence) be grouped?
Generally no, because different detection principles imply possible differences in technical characteristics and performance. Grouping is based on the “same principle” premise. If a company wishes to combine, it must provide comprehensive bridging studies demonstrating clinical equivalence—this is rare.

Q: How can CE IVDR-certified products reuse documents for other countries?
CE IVDR technical files (performance evaluation, clinical evidence, risk management) are robust and can serve as a foundation. However, local content must be added: China may require clinical data for cutoff establishment; Southeast Asia may require local population sample validation; the Middle East requires Arabic labels and local ethics approval. Use the English original of CE files and supplement country-specific requirements.

Post-Market Maintenance and Long-Term Planning

Registration is not the end of compliance. Companies must maintain certificate validity, change records, distributor authorizations, complaint handling, adverse event reporting, recall processes, label versions, and regulatory update records. Many companies invest heavily in obtaining registration but neglect post-market obligations. When a production address changes, a model is expanded, instructions are updated, or the agent is replaced, the certificate may become disconnected from market sales.

AIMEILI recommends integrating this question into an annual international registration plan: prioritize target markets, build a reusable documentation package and country gap list, then schedule submissions, deficiency responses, post-market maintenance, and renewal milestones. This approach not only improves single-country efficiency but also creates a replicable overseas compliance capability that reduces the cost of starting from scratch in each new market.

Content Review and Applicability

Author: AIMEILI Regulatory Editorial Team. Professional review: AIMEILI Medical Device International Registration Project Group. Source principles: priority is given to official regulators, international organizations, standard bodies, and public regulatory information; industry media and project experience are used only for auxiliary judgment. This article is intended for preliminary understanding, document preparation, and project planning, and does not replace the official requirements of the target country’s regulator, test conclusions, or legal advice.